Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial

20251 citationsJournal Article

Authors

Philipp Harter · Philipps University of Marburg

Frederik Marmé · Heidelberg University

Andrés Redondo · Hospital Universitario La Paz

Alexander Reuß · Philipps University of Marburg

Kristina Lindemann · Oslo University Hospital

Christian Kurzeder · Saab (Switzerland)

Els Van Nieuwenhuysen

Abstract

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy HER2/EGFR in Cancer Research

Publication Details

Published in: Journal of Clinical Oncology

Volume 44, Issue 2, pp. 103-116

DOI: 10.1200/jco-25-01210

Field-Weighted Citation Impact: 1.70

Command Palette

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial

Authors

Abstract

Topics & Keywords

Publication Details